Northwestern Mutual Wealth Management Co. Increases Stock Position in Edwards Lifesciences Corp (NYSE:EW)

Northwestern Mutual Wealth Management Co. grew its stake in shares of Edwards Lifesciences Corp (NYSE:EW) by 11.9% in the 1st quarter, according to its most recent filing with the Securities & Exchange Commission. The firm owned 29,780 shares of the medical research company’s stock after buying an additional 3,172 shares during the period. Northwestern Mutual Wealth Management Co.’s holdings in Edwards Lifesciences were worth $5,617,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors also recently made changes to their positions in the company. Princeton Global Asset Management LLC purchased a new stake in Edwards Lifesciences during the 4th quarter worth $26,000. Savior LLC purchased a new stake in Edwards Lifesciences during the 4th quarter worth $27,000. Evolution Wealth Advisors LLC boosted its position in Edwards Lifesciences by 990.9% during the 4th quarter. Evolution Wealth Advisors LLC now owns 120 shares of the medical research company’s stock worth $28,000 after purchasing an additional 109 shares during the period. 1776 Wealth LLC boosted its position in Edwards Lifesciences by 97.6% during the 1st quarter. 1776 Wealth LLC now owns 162 shares of the medical research company’s stock worth $30,000 after purchasing an additional 80 shares during the period. Finally, Sugarloaf Wealth Management LLC purchased a new stake in Edwards Lifesciences during the 4th quarter worth $47,000. 81.22% of the stock is owned by institutional investors.

In related news, VP Larry L. Wood sold 3,566 shares of the stock in a transaction dated Monday, March 2nd. The shares were sold at an average price of $207.00, for a total transaction of $738,162.00. Following the sale, the vice president now owns 120,995 shares in the company, valued at $25,045,965. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, CEO Michael A. Mussallem sold 22,850 shares of the stock in a transaction dated Tuesday, April 7th. The stock was sold at an average price of $202.34, for a total transaction of $4,623,469.00. Following the sale, the chief executive officer now owns 69,976 shares in the company, valued at approximately $14,158,943.84. The disclosure for this sale can be found here. In the last quarter, insiders have sold 95,878 shares of company stock worth $20,047,408. 1.48% of the stock is owned by company insiders.

A number of analysts recently weighed in on the stock. Morgan Stanley upped their price target on shares of Edwards Lifesciences from $241.00 to $250.00 and gave the stock an “overweight” rating in a research report on Friday, April 24th. Wells Fargo & Co cut shares of Edwards Lifesciences from an “overweight” rating to an “equal weight” rating and decreased their price target for the stock from $250.00 to $230.00 in a research report on Tuesday, April 28th. Citigroup upped their price target on shares of Edwards Lifesciences from $240.00 to $255.00 and gave the stock a “buy” rating in a research report on Friday, April 24th. Credit Suisse Group upped their price objective on shares of Edwards Lifesciences from $260.00 to $262.00 and gave the company an “outperform” rating in a research report on Friday, April 24th. Finally, Raymond James upped their price objective on shares of Edwards Lifesciences from $230.00 to $250.00 and gave the company an “outperform” rating in a research report on Friday, April 24th. One analyst has rated the stock with a sell rating, eight have given a hold rating and sixteen have issued a buy rating to the stock. The stock has a consensus rating of “Buy” and an average target price of $247.52.

Shares of Edwards Lifesciences stock opened at $218.81 on Friday. The firm has a market cap of $45.13 billion, a PE ratio of 41.84, a price-to-earnings-growth ratio of 2.75 and a beta of 0.85. The firm’s 50-day simple moving average is $212.94 and its 200-day simple moving average is $222.43. The company has a debt-to-equity ratio of 0.17, a quick ratio of 2.47 and a current ratio of 3.36. Edwards Lifesciences Corp has a 1 year low of $154.52 and a 1 year high of $247.64.

Edwards Lifesciences (NYSE:EW) last issued its earnings results on Thursday, April 23rd. The medical research company reported $1.51 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.29 by $0.22. The business had revenue of $1.13 billion for the quarter, compared to analyst estimates of $1.03 billion. Edwards Lifesciences had a net margin of 24.71% and a return on equity of 31.83%. The company’s revenue for the quarter was up 13.7% on a year-over-year basis. During the same quarter in the prior year, the business posted $1.32 EPS. On average, equities analysts predict that Edwards Lifesciences Corp will post 4.95 earnings per share for the current year.

Edwards Lifesciences Company Profile

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States and internationally. It offers transcatheter heart valve therapy products comprising transcatheter aortic valve replacement, and transcatheter mitral and tricuspid therapies for the nonsurgical replacement of heart valves.

Featured Article: What is a CD ladder?

Institutional Ownership by Quarter for Edwards Lifesciences (NYSE:EW)

Receive News & Ratings for Edwards Lifesciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Edwards Lifesciences and related companies with MarketBeat.com's FREE daily email newsletter.